SAGE Sage Therapeutics
- 12.010
- +0.300+2.56%
- 12.010
- 0.0000.00%
Sage Therapeutics News
Half Year 2024 Results
16 May 2024Download the full press release (PDF)Strong performance driven by innovationSteve Hare, Chief Executive Officer, commented:"Sage performed well in the first half of the year, delivering bro
Sage Therapeutics CE Says Co Open To Partnership On Huntington's Drug; Says There Is A 'Lot Of Inbound Interest'
Sage Therapeutics CE Says Co Open To Partnership On Huntington's Drug; Says There Is A 'Lot Of Inbound Interest'
SAGE Cyber Emerges From Stealth Mode - Announces the Launch of the SAGE Platform to Help CISOs With Cyber Defense Planning and Optimization
NEW YORK, May 13, 2024 /PRNewswire/ -- SAGE Cyber, the world's leading innovator of cybersecurity defense planning and optimization technology, is proud to announce it has emerged from stealth, and w
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Sage Therapeutics to Participate in Upcoming May Investor Conferences
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Sage Therapeutics Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)
Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.
Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.
Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho
Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho
Sage Therapeutics Is Maintained at Neutral by Mizuho
Sage Therapeutics Is Maintained at Neutral by Mizuho
Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17
Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics with a Hold and lowers the price target from $21 to $17.
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment
SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital
SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
Analysis
Price Target
No Data
